The Lancet. Haematology
The most recent articles from:
Lancet Haematol
-
The Lancet. Haematology · Mar 2017
Randomized Controlled TrialEfficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Idelalisib, a selective inhibitor of PI3Kδ, is approved for the treatment of patients with relapsed chronic lymphocytic leukaemia (CLL) in combination with rituximab. We aimed to assess the efficacy and safety of idelalisib in combination with a second-generation anti-CD20 antibody, ofatumumab, in a similar patient population. ⋯ Gilead Sciences, Inc.